Wang, Qinchuan et al. revealed that several immune points (including BTLA, IDO, and CD27) were optimal biomarkers for tumor recurrence and survival in renal cell carcinoma patients, and a high expression level of BTLA was also found to be related to decreased survival [51]. This evidence concerns the gene IDO1 and renal cell carcinoma.